fluorouracil has been researched along with Intestinal Diseases in 40 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Intestinal Diseases: Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs." | 8.93 | Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. ( Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV, 2016) |
| "This study aims to evaluate the effect of berberine-based carbon quantum dots (Ber-CDs) on improving 5-fluorouracil (5-FU)-induced intestinal mucositis in C57BL/6 mice, and explored the mechanisms behind this effect." | 8.31 | Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents. ( He, J; Li, H; Sun, C; Tan, J; Wang, D; Wu, L; Xi, Y; Yan, M, 2023) |
| "FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer." | 7.96 | Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. ( Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 7.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 7.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 7.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| "5-Fluorouracil is one of the most commonly used anticancer drugs for the treatment of various types of cancer but has potential adverse effects such as intestinal mucositis, renal, hepatic, and reproductive organ toxicity." | 7.83 | Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study. ( Al-Asmari, AK; Al-Shahrani, HM; Al-Zahrani, AM; Ali Al Amri, M; Khan, AQ, 2016) |
| "Our results bring support to the hUP1 inhibitor strategy as a novel possibility of prevention and treatment of mucositis during the 5-FU chemotherapy, based on the approach of uridine accumulation in plasma and tissues." | 7.80 | Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. ( Basso, LA; Campos, MM; Lopes, TG; Machado, P; Petersen, GO; Renck, D; Santos, AA; Santos, DS, 2014) |
| "To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis." | 7.74 | Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. ( Assreuy, AM; Brito, GA; Gomes, AS; Mota, JM; Oliveira, RB; Ribeiro, RA; Santos, AA; Soares, PM; Souza, MH, 2008) |
| "In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect." | 7.69 | Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995) |
| "5-Fluorouracil (5-FU) is a front-line cytotoxic therapy." | 5.72 | Thymol ameliorates 5-fluorouracil-induced intestinal mucositis: Evidence of down-regulatory effect on TGF-β/MAPK pathways through NF-κB. ( Al-Amin, MA; Al-Khrashi, LA; Badr, AM; Mahran, YF, 2022) |
| "Intestinal mucositis is one of the major troublesome side effects of anticancer chemotherapy leading to poor patient compliance." | 5.38 | Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. ( Araújo, CV; Azevedo, OG; Costa, TB; Guerrant, RL; Lima, AÂ; Lima, RC; Lucena, HB; Oliveira, BC; Oliveira, RA; Oriá, RB; Ribeiro, RA; Vitek, MP; Warren, CA; Wong, DV; Zaja-Milatovic, S, 2012) |
| "Gastrointestinal mucositis is a common side effect of cancer chemotherapy." | 5.37 | Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Brito, GA; Cunha, FQ; Justino, PF; Lima-Junior, RC; Mota, JM; Ribeiro, RA; Soares, PM; Souza, MH, 2011) |
| "Intestinal mucositis and diarrhea are common manifestations of anticancer regimens that include irinotecan, 5-fluorouracil (5-FU), and other cytotoxic drugs." | 4.93 | Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives. ( Cunha, FQ; Leite, CA; Lima-Júnior, RC; Mota, JM; Ribeiro, RA; Souza, MH; Wanderley, CW; Wong, DV, 2016) |
| "This study aims to evaluate the effect of berberine-based carbon quantum dots (Ber-CDs) on improving 5-fluorouracil (5-FU)-induced intestinal mucositis in C57BL/6 mice, and explored the mechanisms behind this effect." | 4.31 | Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents. ( He, J; Li, H; Sun, C; Tan, J; Wang, D; Wu, L; Xi, Y; Yan, M, 2023) |
| "FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin), a 5-fluorouracil (5-FU)-based chemotherapy regimen, is one of most common therapeutic regimens for colorectal cancer." | 3.96 | Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer. ( Chang, CW; Chen, MJ; Chen, YJ; Chiang Chiau, JS; Chuang, WH; Lee, HC; Li, LH; Liu, CY; Shih, SC; Tsai, TH; Wang, HY; Wang, TE, 2020) |
| "The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood." | 3.85 | Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017) |
| " 5-Fluorouracil (5-FU), widely used for cancer chemotherapy, is known to frequently induce intestinal mucositis accompanied by severe diarrhoea." | 3.85 | Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses. ( Amagase, K; Hamouda, N; Kano, Y; Kato, S; Matsumoto, K; Oikawa, Y; Shimakawa, M; Tanaka, Y, 2017) |
| "5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents." | 3.85 | Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017) |
| "5-Fluorouracil is one of the most commonly used anticancer drugs for the treatment of various types of cancer but has potential adverse effects such as intestinal mucositis, renal, hepatic, and reproductive organ toxicity." | 3.83 | Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study. ( Al-Asmari, AK; Al-Shahrani, HM; Al-Zahrani, AM; Ali Al Amri, M; Khan, AQ, 2016) |
| "Our results bring support to the hUP1 inhibitor strategy as a novel possibility of prevention and treatment of mucositis during the 5-FU chemotherapy, based on the approach of uridine accumulation in plasma and tissues." | 3.80 | Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis. ( Basso, LA; Campos, MM; Lopes, TG; Machado, P; Petersen, GO; Renck, D; Santos, AA; Santos, DS, 2014) |
| "Mice were injected with 5-fluorouracil (5-FU) or saline to induce mucositis and were then treated with GLP-1, GLP-2, GLP-2 (3-33), exendin (9-39) or vehicle." | 3.79 | Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. ( Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS, 2013) |
| "To evaluate gastrointestinal motility during 5-fluorouracil (5-FU)-induced intestinal mucositis." | 3.74 | Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. ( Assreuy, AM; Brito, GA; Gomes, AS; Mota, JM; Oliveira, RB; Ribeiro, RA; Santos, AA; Soares, PM; Souza, MH, 2008) |
| "In 16 advanced colorectal cancer patients with 5-fluorouracil-associated diarrhea, we evaluated the role of bacterial pathogens in the development of this adverse effect." | 3.69 | Have enteric infections a role in 5-fluorouracil-associated diarrhea? ( Cascinu, S; Catalano, G, 1995) |
| "One of the major complications that patients experience during pharmacological treatment is the occurrence of adverse drug reactions (ADRs)." | 2.61 | Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches. ( de Kok, TM; Jennen, DGJ; Kleinjans, JCS; Lemmens, L; Rodrigues, D; Souza, T, 2019) |
| "5-Fluorouracil (5-FU) is a front-line cytotoxic therapy." | 1.72 | Thymol ameliorates 5-fluorouracil-induced intestinal mucositis: Evidence of down-regulatory effect on TGF-β/MAPK pathways through NF-κB. ( Al-Amin, MA; Al-Khrashi, LA; Badr, AM; Mahran, YF, 2022) |
| "Cancer chemotherapy is frequently accompanied by adverse effects, such as diarrhoea and leukopenia, which lead to malnutrition and a decrease in the patients' quality of life." | 1.51 | Nutritional treatment with an immune-modulating enteral formula alleviates 5-fluorouracil-induced adverse effects in rats. ( Ashida, K; Nakamura, K; Sasayama, A; Tonouchi, H; Yamaji, T, 2019) |
| "Altogether, 11 components were identified or tentatively characterized in dosed plasma." | 1.51 | The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice. ( Gao, J; Gao, W; Jin, Z; Man, S; Zhang, J; Zheng, H, 2019) |
| "Intestinal mucositis is one of the major troublesome side effects of anticancer chemotherapy leading to poor patient compliance." | 1.38 | Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis. ( Araújo, CV; Azevedo, OG; Costa, TB; Guerrant, RL; Lima, AÂ; Lima, RC; Lucena, HB; Oliveira, BC; Oliveira, RA; Oriá, RB; Ribeiro, RA; Vitek, MP; Warren, CA; Wong, DV; Zaja-Milatovic, S, 2012) |
| "Gastrointestinal mucositis is a common side effect of cancer chemotherapy." | 1.37 | Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Brito, GA; Cunha, FQ; Justino, PF; Lima-Junior, RC; Mota, JM; Ribeiro, RA; Soares, PM; Souza, MH, 2011) |
| " These and control animals were sacrificed and, using inverted sacs, the rate of absorption of either dimethylnitrosamine and benzo(a)pyrene determined." | 1.26 | Use of inverted intestinal sacs to assess the effect of gastrointestinal insult on carcinogen absorption. ( Capel, ID; Cosier, RS; Pinnock, MH; Williams, DC, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (20.00) | 18.7374 |
| 1990's | 5 (12.50) | 18.2507 |
| 2000's | 4 (10.00) | 29.6817 |
| 2010's | 17 (42.50) | 24.3611 |
| 2020's | 6 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Khrashi, LA | 1 |
| Badr, AM | 1 |
| Al-Amin, MA | 1 |
| Mahran, YF | 1 |
| Chen, KJ | 1 |
| Huang, YL | 1 |
| Kuo, LM | 1 |
| Chen, YT | 1 |
| Hung, CF | 1 |
| Hsieh, PW | 1 |
| Wu, L | 1 |
| Xi, Y | 1 |
| Yan, M | 1 |
| Sun, C | 1 |
| Tan, J | 1 |
| He, J | 1 |
| Li, H | 1 |
| Wang, D | 1 |
| Nakamura, K | 1 |
| Tonouchi, H | 1 |
| Sasayama, A | 1 |
| Yamaji, T | 1 |
| Ashida, K | 1 |
| Chang, CW | 1 |
| Lee, HC | 1 |
| Li, LH | 1 |
| Chiang Chiau, JS | 1 |
| Wang, TE | 1 |
| Chuang, WH | 1 |
| Chen, MJ | 1 |
| Wang, HY | 1 |
| Shih, SC | 1 |
| Liu, CY | 1 |
| Tsai, TH | 1 |
| Chen, YJ | 1 |
| Hu, M | 1 |
| Wu, X | 1 |
| Luo, M | 1 |
| Wei, H | 1 |
| Xu, D | 1 |
| Xu, F | 1 |
| Fideles, LS | 1 |
| de Miranda, JAL | 1 |
| Martins, CDS | 1 |
| Barbosa, MLL | 1 |
| Pimenta, HB | 1 |
| Pimentel, PVS | 1 |
| Teixeira, CS | 1 |
| Scafuri, MAS | 1 |
| Façanha, SO | 1 |
| Barreto, JEF | 1 |
| Carvalho, PMM | 1 |
| Scafuri, AG | 1 |
| Araújo, JL | 1 |
| Rocha, JA | 1 |
| Vieira, IGP | 1 |
| Ricardo, NMPS | 1 |
| da Silva Campelo, M | 1 |
| Ribeiro, MENP | 1 |
| de Castro Brito, GA | 1 |
| Cerqueira, GS | 1 |
| Hamouda, N | 2 |
| Sano, T | 1 |
| Oikawa, Y | 2 |
| Ozaki, T | 1 |
| Shimakawa, M | 2 |
| Matsumoto, K | 2 |
| Amagase, K | 2 |
| Higuchi, K | 1 |
| Kato, S | 2 |
| Kano, Y | 1 |
| Tanaka, Y | 1 |
| Liu, Z | 1 |
| Xie, W | 1 |
| Li, M | 1 |
| Teng, N | 1 |
| Liang, X | 1 |
| Zhang, Z | 1 |
| Yang, Z | 2 |
| Wang, X | 1 |
| de Freitas-Blanco, VS | 1 |
| Monteiro, KM | 1 |
| de Oliveira, PR | 1 |
| de Oliveira, ECS | 1 |
| de Oliveira Braga, LE | 1 |
| de Carvalho, JE | 1 |
| Ferreira Rodrigues, RA | 1 |
| Zheng, H | 1 |
| Gao, J | 1 |
| Man, S | 1 |
| Zhang, J | 1 |
| Jin, Z | 1 |
| Gao, W | 1 |
| Rodrigues, D | 1 |
| Souza, T | 1 |
| Jennen, DGJ | 1 |
| Lemmens, L | 1 |
| Kleinjans, JCS | 1 |
| de Kok, TM | 1 |
| Renck, D | 1 |
| Santos, AA | 2 |
| Machado, P | 1 |
| Petersen, GO | 1 |
| Lopes, TG | 1 |
| Santos, DS | 1 |
| Campos, MM | 1 |
| Basso, LA | 1 |
| Al-Asmari, AK | 1 |
| Al-Zahrani, AM | 1 |
| Khan, AQ | 1 |
| Al-Shahrani, HM | 1 |
| Ali Al Amri, M | 1 |
| Chen, D | 1 |
| Zhao, J | 1 |
| Wang, H | 1 |
| An, N | 1 |
| Zhou, Y | 1 |
| Fan, J | 1 |
| Luo, J | 1 |
| Su, W | 1 |
| Liu, C | 1 |
| Li, J | 1 |
| Yoshida, Y | 1 |
| Kawabata, R | 1 |
| Yoshikawa, M | 1 |
| Kameda, C | 1 |
| Koga, C | 1 |
| Murakami, M | 1 |
| Hitora, T | 1 |
| Hirota, M | 1 |
| Ikenaga, M | 1 |
| Shimizu, J | 1 |
| Miwa, H | 1 |
| Hasegawa, J | 1 |
| Asahara, T | 1 |
| Takahashi, A | 1 |
| Yuki, N | 1 |
| Kaji, R | 1 |
| Takahashi, T | 1 |
| Nomoto, K | 1 |
| Ribeiro, RA | 4 |
| Wanderley, CW | 1 |
| Wong, DV | 2 |
| Mota, JM | 3 |
| Leite, CA | 1 |
| Souza, MH | 3 |
| Cunha, FQ | 2 |
| Lima-Júnior, RC | 2 |
| Soares, PM | 2 |
| Justino, PF | 1 |
| Brito, GA | 2 |
| Azevedo, OG | 1 |
| Oliveira, RA | 1 |
| Oliveira, BC | 1 |
| Zaja-Milatovic, S | 1 |
| Araújo, CV | 1 |
| Costa, TB | 1 |
| Lucena, HB | 1 |
| Lima, RC | 1 |
| Warren, CA | 1 |
| Lima, AÂ | 1 |
| Vitek, MP | 1 |
| Guerrant, RL | 1 |
| Oriá, RB | 1 |
| Prisciandaro, LD | 1 |
| Geier, MS | 1 |
| Chua, AE | 1 |
| Butler, RN | 1 |
| Cummins, AG | 1 |
| Sander, GR | 1 |
| Howarth, GS | 1 |
| Kissow, H | 1 |
| Hartmann, B | 1 |
| Holst, JJ | 1 |
| Poulsen, SS | 1 |
| BALLERINI, G | 1 |
| BOSI, L | 1 |
| CASTOLDI, GL | 1 |
| RICCI, N | 1 |
| NASH, DT | 1 |
| BRIN, M | 1 |
| Zlotnik, Y | 1 |
| Patya, M | 1 |
| Vanichkin, A | 1 |
| Novogrodsky, A | 1 |
| Gomes, AS | 1 |
| Oliveira, RB | 1 |
| Assreuy, AM | 1 |
| Maisin, H | 1 |
| Anckaert, MA | 1 |
| De Coster, BM | 1 |
| Capel, ID | 1 |
| Cosier, RS | 1 |
| Pinnock, MH | 1 |
| Williams, DC | 1 |
| Chevreau, N | 1 |
| Wang, Y | 1 |
| Funk-Archuleta, M | 1 |
| Cascinu, S | 1 |
| Catalano, G | 1 |
| Orazi, A | 1 |
| Du, X | 1 |
| Kashai, M | 1 |
| Williams, DA | 1 |
| Rakovitch, E | 1 |
| Fyles, AW | 1 |
| Pintilie, M | 1 |
| Leung, PM | 1 |
| Lokich, J | 1 |
| Huang, FS | 1 |
| Kemp, CJ | 1 |
| Williams, JL | 1 |
| Erwin, CR | 1 |
| Warner, BW | 1 |
| Bounous, G | 2 |
| Maestracci, D | 1 |
| Jehad Feddah, M | 1 |
| Vázquez Gallego, JM | 1 |
| Gómez Bosque, O | 1 |
| Nakamura, J | 1 |
| Katayama, M | 1 |
| Nishida, K | 1 |
| Sasaki, H | 1 |
| Gentile, JM | 1 |
| Hugon, J | 1 |
| Gear, EV | 1 |
3 reviews available for fluorouracil and Intestinal Diseases
| Article | Year |
|---|---|
Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Fluorouracil; Humans; Intestinal Diseases; Protein Kinase I | 2019 |
Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights into pathogenesis and therapeutic perspectives.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cytokines; Fluorou | 2016 |
Dobbins WO 3d,+DOBBINS WO III: Rectal biopsy. A review of its diagnostic usefulness.
Topics: Amyloidosis; Biopsy; Colitis, Ulcerative; Crohn Disease; Cystic Fibrosis; Cysts; Deficiency Diseases | 1968 |
37 other studies available for fluorouracil and Intestinal Diseases
| Article | Year |
|---|---|
Thymol ameliorates 5-fluorouracil-induced intestinal mucositis: Evidence of down-regulatory effect on TGF-β/MAPK pathways through NF-κB.
Topics: Animals; Chymases; Fluorouracil; Intestinal Diseases; MAP Kinase Signaling System; Mucositis; NF-kap | 2022 |
Protective role of casuarinin from Melastoma malabathricum against a mouse model of 5-fluorouracil-induced intestinal mucositis: Impact on inflammation and gut microbiota dysbiosis.
Topics: Animals; Disease Models, Animal; Dysbiosis; Fluorouracil; Gastrointestinal Diseases; Gastrointestina | 2022 |
Berberine-Based Carbon Quantum Dots Improve Intestinal Barrier Injury and Alleviate Oxidative Stress in C57BL/6 Mice with 5-Fluorouracil-Induced Intestinal Mucositis by Enhancing Gut-Derived Short-Chain Fatty Acids Contents.
Topics: Animals; Berberine; Fatty Acids, Volatile; Fluorouracil; Intestinal Diseases; Intestinal Mucosa; Mic | 2023 |
Nutritional treatment with an immune-modulating enteral formula alleviates 5-fluorouracil-induced adverse effects in rats.
Topics: Animals; Body Weight; Cultured Milk Products; Dietary Supplements; Disease Models, Animal; Eating; E | 2019 |
Fecal Microbiota Transplantation Prevents Intestinal Injury, Upregulation of Toll-Like Receptors, and 5-Fluorouracil/Oxaliplatin-Induced Toxicity in Colorectal Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Colorectal Neo | 2020 |
Lactobacillus rhamnosus FLRH93 protects against intestinal damage in mice induced by 5-fluorouracil.
Topics: Animals; Disease Models, Animal; Female; Fluorouracil; Ileum; Interleukin-1beta; Intestinal Diseases | 2020 |
Role of Rutin in 5-Fluorouracil-Induced Intestinal Mucositis: Prevention of Histological Damage and Reduction of Inflammation and Oxidative Stress.
Topics: Animals; Fluorouracil; Inflammation; Intestinal Diseases; Male; Mice; Mucositis; Oxidative Stress; R | 2020 |
Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cyto | 2017 |
Probiotic Bifidobacterium bifidum G9-1 attenuates 5-fluorouracil-induced intestinal mucositis in mice via suppression of dysbiosis-related secondary inflammatory responses.
Topics: Animals; Apoptosis; Bifidobacterium bifidum; Body Weight; Diarrhea; Dysbiosis; Fluorouracil; Inflamm | 2017 |
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect | 2017 |
Spilanthol, the Principal Alkylamide from Acmella oleracea, Attenuates 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
Topics: Animals; Asteraceae; Fluorouracil; Intestinal Diseases; Jejunum; Male; Mice; Mucositis; Polyunsatura | 2019 |
The protective effects of Aquilariae Lignum Resinatum extract on 5-Fuorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Diarrhea; Fluorouracil; Intestinal Diseases; Male; Medicin | 2019 |
Human uridine phosphorylase-1 inhibitors: a new approach to ameliorate 5-fluorouracil-induced intestinal mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Enzyme Inhibitors; Female; Fluorouracil; Humans; Intestina | 2014 |
Taurine ameliorates 5-flourouracil-induced intestinal mucositis, hepatorenal and reproductive organ damage in Wistar rats: A biochemical and histological study.
Topics: Animals; Dose-Response Relationship, Drug; Fluorouracil; Intestinal Diseases; Intestines; Kidney; Li | 2016 |
Oxytocin evokes a pulsatile PGE2 release from ileum mucosa and is required for repair of intestinal epithelium after injury.
Topics: Animals; Antineoplastic Agents; Calcium; Cyclooxygenase 2; Dextran Sulfate; Dinoprostone; Disease Mo | 2015 |
[A Case of Penetrating Diverticulum of the Small Intestine that Occurred during Chemotherapy for Esophageal Cancer].
Topics: Abdominal Abscess; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcin | 2015 |
Protective Effect of a Synbiotic against Multidrug-Resistant Acinetobacter baumannii in a Murine Infection Model.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Animals; Anti-Bacterial Agents; Bifidobacterium; | 2016 |
Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Cytokines; Duodenum; Fluorouracil; Ginkgolides; Intestinal | 2011 |
Apolipoprotein E COG 133 mimetic peptide improves 5-fluorouracil-induced intestinal mucositis.
Topics: Animals; Apolipoproteins E; Apoptosis; Biomimetic Materials; Cell Movement; Cell Proliferation; Cell | 2012 |
Probiotic factors partially prevent changes to caspases 3 and 7 activation and transepithelial electrical resistance in a model of 5-fluorouracil-induced epithelial cell damage.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cells, Cultured; Electric | 2012 |
Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis.
Topics: Animals; Antimetabolites, Antineoplastic; Female; Fluorouracil; Glucagon-Like Peptide 1; Glucagon-Li | 2013 |
[Experimental enteropathy induced by 5-fluorouracil in the rat].
Topics: Animals; Disease; Fluorouracil; Intestinal Diseases; Intestine, Small; Intestines; Rats; Uracil | 1961 |
MALABSORPTION IN MALIGNANT CARCINOID WITH NORMAL 5 HIAA.
Topics: Blood Chemical Analysis; Celiac Disease; Fluorouracil; Hydroxyindoleacetic Acid; Indoleacetic Acids; | 1964 |
Tyrphostins reduce chemotherapy-induced intestinal injury in mice: assessment by a biochemical assay.
Topics: Animals; Antineoplastic Agents; Cisplatin; Female; Fluorouracil; gamma-Glutamyltransferase; Intestin | 2005 |
Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carbachol; Fluorouracil; Gastric Emptying; Gast | 2008 |
[Combination chemotherapy and radiotherapy. Differential effect, on the intestinal syndrome, of fractionated irradiation with fractionated drug administration].
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; Female; Fluorouracil; Intestinal Dise | 1982 |
Use of inverted intestinal sacs to assess the effect of gastrointestinal insult on carcinogen absorption.
Topics: Animals; Aspirin; Benzopyrenes; Carcinogens; Cold Temperature; Dimethylnitrosamine; Dose-Response Re | 1981 |
Effect of diets on 5-fluorouracil and cyclophosphamide toxicity.
Topics: Animals; Caseins; Cyclophosphamide; Dietary Proteins; Fluorouracil; Intestinal Diseases; Intestines; | 1995 |
Have enteric infections a role in 5-fluorouracil-associated diarrhea?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bacterial Infections; Colorectal Neoplasms; Diarrhea; | 1995 |
Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cytoplasm; Fluorouracil; Interle | 1996 |
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas | 1997 |
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Fluorouracil; Humans; Intestinal Di | 2000 |
Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury.
Topics: Animals; Antineoplastic Agents; Enteritis; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Ge | 2002 |
Use of an elemental diet in animals during treatment with 5-fluorouracil (NSC-19893).
Topics: Animals; Caseins; Diet; Drug Tolerance; Fluorouracil; gamma-Glutamyltransferase; Hydrolysis; Intesti | 1976 |
[Morphological changes induced by 5-fluorouracil in the intestinal mucosa. I. Observations with the optical microscope].
Topics: Animals; Fluorouracil; Intestinal Diseases; Intestinal Mucosa; Male; Rats | 1978 |
An assessment of mucosal damage in vivo: effect of oral pretreatment with 5-fluorouracil on the intestinal first-pass metabolism of salicylamide in rabbits.
Topics: Administration, Oral; Animals; Fluorouracil; Intestinal Diseases; Intestinal Mucosa; Male; Rabbits; | 1992 |
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
Topics: Aged; Amino Acids; Animals; Biopsy; Diarrhea; Diet Therapy; Dietary Proteins; Female; Fluorouracil; | 1971 |